| 1. Provider experiences with three- and six-month antiretroviral therapy dispensing for stable clients in Zambia. Phiri K, McBride K, Siwale Z, Hubbard J, Bardon A, Moucheraud C, Haambokoma M, Pisa PT, Moyo C, Hoffman RM.AIDS Care. 2021 Apr;33(4):541-547. doi: 10.1080/09540121.2020.1755010. Epub 2020 May 4.PMID: 32363910 |
| 2. Factors associated with viral load non-suppression in people living with HIV on ART in Nigeria: cross-sectional analysis from 2017 to 2021. Tomescu S, Crompton T, Adebayo J, Akpan F, Dauda DS, Allen Z, Ondura EO, Wose Kinge C, Chasela C, Pisa P. BMJ Open. 2023 May 11;13(5):e065950. doi: 10.1136/bmjopen-2022-065950.PMID: 37169497 Free PMC article. |
| 3. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. Hoffman RM, Moyo C, Balakasi KT, Siwale Z, Hubbard J, Bardon A, Fox MP, Kakwesa G, Kalua T, Nyasa-Haambokoma M, Dovel K, Campbell PM, Tseng CH, Pisa PT, Cele R, Gupta S, Benade M, Long L, Xulu T, Sanne I, Rosen S.Lancet Glob Health. 2021 May;9(5):e628-e638. doi: 10.1016/S2214-109X(21)00039-5.PMID: 33865471 Clinical Trial. |
| 4. Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia. Hoffman RM, Balakasi K, Bardon AR, Siwale Z, Hubbard J, Kakwesa G, Haambokoma M, Kalua T, Pisa P, Moyo C, Dovel K, Xulu T, Sanne I, Fox M, Rosen S. 2020 Mar 1;34(3):475-479. doi: 10.1097/QAD.0000000000002435. PMID: 31764076 |
| 5. Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts. Maskew M, Sharpey-Schafer K, De Voux L, Crompton T, Bor J, Rennick M, Chirowodza A, Miot J, Molefi S, Onaga C, Majuba P, Sanne I, Pisa P. Sci Rep. 2022 Jul 26;12(1):12715. doi: 10.1038/s41598-022-16062-0.PMID: 35882962 Free PMC article. |
| 6. Access to HIV care and treatment for migrants between Lesotho and South Africa: a mixed methods study. Faturiyele I, Karletsos D, Ntene-Sealiete K, Musekiwa A, Khabo M, Mariti M, Mahasha P, Xulu T, Pisa PT; EQUIP Innovation for Health Team. BMC Public Health. 2018 May 29;18(1):668. doi: 10.1186/s12889-018-5594-3. PMID: 29843667 Free PMC article. |
| 7. Factors associated with an interruption in treatment of people living with HIV in USAID-supported states in Nigeria: a retrospective study from 2000-2020. Tomescu S, Crompton T, Adebayo J, Kinge CW, Akpan F, Rennick M, Chasela C, Ondura E, Dauda DS, Pisa PT. BMC Public Health. 2021 Nov 30;21(1):2194. doi: 10.1186/s12889-021-12264-9. PMID: 34847909 Free PMC article. |
| 8. Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste. Ovens W, Tomescu S, Harrison E, Crampton T, De Nooy A, Jassat W, Banoo S, Pisa P, Sanne I. S Afr Med J. 2022 Feb 1;112(2):13501. PMID: 35139989 |
| 9. Quality of service and continuous quality improvement in voluntary medical male circumcision programme across four provinces in South Africa: Longitudinal and cross-sectional programme data. Nyengerai T, Phohole M, Iqaba N, Kinge CW, Gori E, Moyo K, Chasela C. PLoS One. 2021 Aug 5;16(8):e0254850. doi: 10.1371/journal.pone.0254850. eCollection 2021.PMID: 34351933 Free PMC article. |
| 10. Persistent Symptoms among Frontline Health Workers Post-Acute COVID-19 Infection. Wose Kinge C, Hanekom S, Lupton-Smith A, Akpan F, Mothibi E, Maotoe T, Lebatie F, Majuba P, Sanne I, Chasela C. Int J Environ Res Public Health. 2022 May 13;19(10):5933. doi: 10.3390/ijerph19105933. PMID: 35627472 Free PMC article. |
| 11. Voluntary medical male circumcision in selected provinces in South Africa: Outcomes from a programmatic setting. Moyo K, Igaba N, Wose Kinge C, Chasela C, Phohole M, Grove S, Makura C, Mudau L, Taljaard D, Rech D, Ramkissoon A, Searle C, Majuba P, Sanne I. PLoS One. 2022 Sep 23;17(9):e0270545. doi:10.1371/journal.pone.0270545. eCollection 2022.PMID: 36149904 Free PMC article. |
| 12. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Wose Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP.J Viral Hepat. 2022 Jun;29(6):474-486. doi: 10.1111/jvh.13672. Epub 2022 Mar 30. PMID: 35278339 Free PMC article. |
| 13. Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine. Antoniak S, Chasela CS, Freiman MJ, Stopolianska Y, Barnard T, Gandhi MM, Liulchuk M, Tsenilova Z, Viktor T, Dible J, Wose Kinge C, Akpan F, Minior T, Sigwebela N, Mohamed S, Barralon M, Marange F, Cavenaugh C, Horst CV, Antonyak S, Xulu T, Chew KW, Sanne I, Rosen S; for EQUIP Health.JGH Open. 2022 Nov 17;6(12):894-903. doi: 10.1002/jgh3.12839. eCollection 2022 Dec.PMID: 36514496 Free PMC article. |
| 14. Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar. Min Thaung Y, Chasela CS, Chew KW, Minior T, Lwin AA, Sein YY, Drame N, Marange F, van der Horst C, Thwin HT, Freiman MJ, Gandhi MM, Bijl M, Wose Kinge C, Rosen S, Thura S, Mohamed S, Xulu T, Naing AY, Barralon M, Cavenaugh C, Kyi KP, Sanne I; for EQUIP Health. J Viral Hepat. 2021 Jan;28(1):147-158. doi: 10.1111/jvh.13405. Epub 2020 Oct 9. PMID: 32935438 Free PMC article. |
| 15. Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients. Nichols BE, Cele R, Lekodeba N, Tukei B, Ngorima-Mabhena N, Tiam A, Maotoe T, Sejana MV, Faturiyele IO, Chasela C, Rosen S, Fatti G.J Int AIDS Soc. 2021 Apr;24(4):e25692. doi: 10.1002/jia2.25692. PMID:33838012 Free PMC article. |
| 16. Out-of-Facility Multimonth Dispensing of Antiretroviral Treatment: A Pooled Analysis Using Individual Patient Data From Cluster-Randomized Trials in Southern Africa. Lopes J, Grimwood A, Ngorima-Mabhena N, Tiam A, Tukei BB, Kasu T, Mahachi N, Mothibi E, Tukei V, Chasela C, Lombard C, Fatti G.J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):477-486. doi: 10.1097/QAI.0000000000002797. PMID:34506343 |
| 17. Community-based differentiated service delivery models incorporating multi-month dispensing of antiretroviral treatment for newly stable people living with HIV receiving single annual clinical visits: a pooled analysis of two cluster-randomized trials in southern Africa. Fatti G, Ngorima-Mabhena N, Tiam A, Tukei BB, Kasu T, Muzenda T, Maile K, Lombard C, Chasela C, Grimwood A. J Int AIDS Soc. 2021 Oct;24 Suppl 6(Suppl 6):e25819. doi: 10.1002/jia2.25819. PMID:34713614 Free PMC article. |
| 18. Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial. Tukei BB, Fatti G, Tiam A, Ngorima-Mabhena N, Tukei VJ, Tshabalala I, Sejana VM, Muzenda T, Mokoroane LM, Sehlabo L, Maotoe T, Mirembe JK, Membe I, Akpan F, Maile K, Faturiyele I, Xulu T, Minior T, Sanne I, Chasela C; for EQUIP Health.J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):280-291. doi: 10.1097/QAI.0000000000002439. PMID:32665460 Clinical Trial. |
| 19. Outcomes of Three- Versus Six-Monthly Dispensing of Antiretroviral Treatment (ART) for Stable HIV Patients in Community ART Refill Groups: A Cluster-Randomized Trial in Zimbabwe. Fatti G, Ngorima-Mabhena N, Mothibi E, Muzenda T, Choto R, Kasu T, Tafuma TA, Mahachi N, Takarinda KC, Apollo T, Mugurungi O, Chasela C, Hoffman RM, Grimwood A.J Acquir Immune Defic Syndr. 2020 Jun 1;84(2):162-172. doi: 10.1097/QAI.0000000000002333.PMID:32097252 Free PMC article. Clinical Trial. |
| 20. Economic evaluation of a cluster randomized, non-inferiority trial of differentiated service delivery models of HIV treatment in Zimbabwe. Benade M, Nichols BE, Fatti G, Kuchukhidze S, Takarinda K, Mabhena-Ngorima N, Grimwood A, Rosen S. PLOS Glob Public Health. 2023 Mar 13;3(3):e0000493. doi: 10.1371/journal.pgph.0000493. eCollection 2023.PMID:36962960 Free PMC article. |
| 21. The effectiveness and cost-effectiveness of 3- vs. 6-monthly dispensing of antiretroviral treatment (ART) for stable HIV patients in community ART-refill groups in Zimbabwe: study protocol for a pragmatic, cluster-randomized trial. Fatti G, Ngorima-Mabhena N, Chirowa F, Chirwa B, Takarinda K, Tafuma TA, Mahachi N, Chikodzore R, Nyadundu S, Ajayi CA, Mutasa-Apollo T, Mugurungi O, Mothibi E, Hoffman RM, Grimwood A. 2018 Jan 29;19(1):79. doi: 10.1186/s13063-018-2469 PMID:29378662 Free PMC article. |
| 22. Monitoring viral load for the last mile: what will it cost? Nichols BE, Girdwood SJ, Crompton T, Stewart-Isherwood L, Berrie L, Chimhamhiwa D, Moyo C, Kuehnle J, Stevens W, Rosen S; EQUIP Health.J Int AIDS Soc. 2019 Sep;22(9):e25337. doi: 10.1002/jia2.25337.PMID: 31515967 Free PMC article. |
| 23. The early-stage comprehensive costs of routine PrEP implementation and scale-up in Zambia. Hendrickson C, Long LC, van Rensburg C, Claassen CW, Njelesani M, Moyo C, Mulenga L, O’Bra H, Russell CA, Nichols BE. PLOS Glob Public Health. 2022 Nov 2;2(11):e0001246. doi: 10.1371/journal.pgph.0001246. eCollection 2022. PMID: 36962684 Free PMC article. |
| 24. Community-based delivery of HIV treatment in Zambia: costs and outcomes. Nichols BE, Cele R, Jamieson L, Long LC, Siwale Z, Banda P, Moyo C, Rosen S. AIDS. 2021 Feb 2;35(2):299-306. d10.1097/QAD.0000000000002737.PMID: 33170578 Free PMC article. |
| 25. Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi. Nichols BE, Offorjebe OA, Cele R, Shaba F, Balakasi K, Chivwara M, Hoffman RM, Long LC, Rosen S, Dovel K.J Int AIDS Soc. 2020 Sep;23(9):e25612. doi: 10.1002/jia2.25612. PMID: 32909387 Free PMC article.Clinical Trial. |
| 26. Factors associated with men’s health facility attendance as clients and caregivers in Malawi: a community-representative survey. Thorp M, Balakasi KT, Mphande M, Robson I, Khan S, Stillson C, Doi N, Nichols BE, Dovel K. BMC Public Health. 2022 Oct 12;22(1):1904. doi: 10.1186/s12889-022-14300-8. PMID: 36224573 Free PMC article. |
| 27. Frequency of visits to health facilities and HIV services offered to men, Malawi. Dovel K, Balakasi K, Gupta S, Mphande M, Robson I, Khan S, Amberbir A, Stilson C, van Oosterhout JJ, Doi N, Nichols BE. Bull World Health Organ. 2021 Sep 1;99(9):618-626. doi: 10.2471/BLT.20.278994. Epub 2021 Jun 29.PMID: 34475599 Free PMC article. |
| 28. Effect of facility-based HIV self-testing on uptake of testing among outpatients in Malawi: a cluster-randomised trial. Dovel K, Shaba F, Offorjebe OA, Balakasi K, Nyirenda M, Phiri K, Gupta SK, Wong V, Tseng CH, Nichols BE, Cele R, Lungu E, Masina T, Coates TJ, Hoffman RM.Lancet Glob Health. 2020 Feb;8(2):e276-e287. doi: 10.1016/S2214-109X(19)30534-0.PMID: 31981557 Clinical Trial. |
| 29. Facility-based HIV self-testing strategies may substantially and cost-effectively increase the number of men and youth tested for HIV in Malawi: results from an individual-based mathematical model. Nichols BE, de Nooy A, Benade M, Balakasi K, Mphande M, Rao G, Claassen CW, Khan S, Stillson C, Russell CA, Doi N, Dovel K. J Int AIDS Soc. 2022 Oct;25(10):e26020. doi: 10.1002/jia2.26020.PMID: 36251161 Free PMC article. |
| 30. Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients. Nichols BE, Cele R, Lekodeba N, Tukei B, Ngorima-Mabhena N, Tiam A, Maotoe T, Sejana MV, Faturiyele IO, Chasela C, Rosen S, Fatti G.J Int AIDS Soc. 2021 Apr;24(4):e25692. doi: 10.1002/jia2.25692.PMID: 33838012 Free PMC article. |
| 31. Optimizing viral load testing access for the last mile: Geospatial cost model for point of care instrument placement. Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S.PLoS One. 2019 Aug 26;14(8):e0221586. doi: 10.1371/journal.pone.0221586. eCollection 2019. PMID: 31449559 Free PMC article. |
| 32. Individual- and Facility-Level Factors Associated with Facility Testing among Men in Malawi: Findings from a Representative Community Survey. Balakasi K, Nichols BE, Mphande M, Stillson C, Khan S, Kalande P, Robson I, Sanena M, Ng’ona K, van Oosterhout JJ, Doi N, Dovel K. Diagnostics (Basel). 2021 May 26;11(6):950. doi: 10.3390/diagnostics11060950. PMID: 34073217 Free PMC article. |
| 33. Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. Nichols BE, Girdwood SJ, Shibemba A, Sikota S, Gill CJ, Mwananyanda L, Noble L, Stewart-Isherwood L, Scott L, Carmona S, Rosen S, Stevens W. Clin Infect Dis. 2020 Mar 3;70(6):1014-1020. doi: 10.1093/cid/ciz338. PMID: 31321438 Free PMC article. |
| 34. Impact of a borderless sample transport network for scaling up viral load monitoring: results of a geospatial optimization model for Zambia. Nichols BE, Girdwood SJ, Crompton T, Stewart-Isherwood L, Berrie L, Chimhamhiwa D, Moyo C, Kuehnle J, Stevens W, Rosen S; EQUIP Health.J Int AIDS Soc. 2018 Dec;21(12):e25206. doi: 10.1002/jia2.25206.PMID: 30515997 Free PMC article. |
| 35. Economic evaluation of a cluster randomized, non-inferiority trial of differentiated service delivery models of HIV treatment in Zimbabwe. Benade M, Nichols BE, Fatti G, Kuchukhidze S, Takarinda K, Mabhena-Ngorima N, Grimwood A, Rosen S.PLOS Glob Public Health. 2023 Mar 13;3(3):e0000493. doi: 10.1371/journal.pgph.0000493. eCollection 2023.PMID: 36962960 Free PMC article. |
| 36. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine. Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi MM, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew KW, van der Horst C, Tsenilova Z, Sanne I.BMC Infect Dis. 2022 Jul 27;22(1):650. doi: 10.1186/s12879-022-07615-9.PMID: 35896987 Free PMC article. |
| 37. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Wose Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP.J Viral Hepat. 2022 Jun;29(6):474-486. doi: 10.1111/jvh.13672. Epub 2022 Mar 30.PMID: 35278339 Free PMC article. |
